March 13, 2013
Combination therapy with cytarabine, bendamustine and rituximab was associated with strong response-related outcomes in mantle cell lymphoma, according to results of a phase 2 study.
The researchers investigated the R-BAC combination — cytarabine, bendamustine (Treanda, Cephalon) and rituximab (Rituxan, Genentech/Idec Pharmaceuticals) — in 40 patients with mantle cell lymphoma. All participants were aged at least 65 years (median age, 70 years). Twenty patients were previously untreated, and the other 20 had relapsed or refractory disease after one immunochemotherapy regimen.